Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

OBJECTIVE: The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) in patients with relapsing–remitting multiple sclerosis. We report the results of long-term (up to 4.5 years) extension of TRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jeffrey A, Khatri, Bhupendra, Barkhof, Frederik, Comi, Giancarlo, Hartung, Hans-Peter, Montalban, Xavier, Pelletier, Jean, Stites, Tracy, Ritter, Shannon, von Rosenstiel, Philipp, Tomic, Davorka, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853559/
https://www.ncbi.nlm.nih.gov/pubmed/26111826
http://dx.doi.org/10.1136/jnnp-2015-310597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853559/
https://www.ncbi.nlm.nih.gov/pubmed/26111826
http://dx.doi.org/10.1136/jnnp-2015-310597

Ejemplares similares